MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Consensus Ratings for Nektar Therapeutics (NASDAQ:NKTR) (?)
Ratings Breakdown: 1 Sell Rating(s), 6 Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $15.50 (43.12% upside)

Current Analysts' Coverage Summary for Nektar Therapeutics (NASDAQ:NKTR)
Show:
DateFirmActionRatingPrice TargetActions
8/24/2015William BlairReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Piper JaffrayBoost Price TargetOverweight$13.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/6/2015Brean CapitalReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/19/2015Roth CapitalReiterated RatingBuy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015JPMorgan Chase & Co.Lower Price TargetOverweight$19.00 -> $17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015Jefferies GroupLower Price TargetBuy$17.00 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/17/2014Bank of AmericaReiterated RatingUnderperform$10.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/26/2014Ladenburg ThalmannInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2014MKM PartnersReiterated RatingNeutral$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/27/2013Cowen and CompanyReiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/28/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha